Research suggests that the effectiveness of bispecific antibodies in treating Crimean-Congo hemorrhagic fever virus is impacted by avidity and variable domain spacing. The therapeutic potency of these antibodies appears to be influenced by these factors. The relationship between these elements and the antibodies' potency is being explored.